Literature DB >> 3014123

Quantitative analysis of the selectivity of radioligands for subtypes of beta adrenergic receptors.

K A Neve, P McGonigle, P B Molinoff.   

Abstract

In tissues with two classes of binding sites for a drug, it is common to estimate the proportion of each class of binding site by inhibiting the binding of a radioligand with a selective unlabeled ligand. Accurate estimates of the density of each class of binding site, however, will be obtained only if the radioligand is nonselective or used at a concentration that saturates both classes of binding sites. A method of simultaneous regression analysis of multiple inhibition curves, using the program MLAB on the PROPHET system, was used to quantify the selectivity of radioligands for beta-1 or beta-2 adrenergic receptors. The selectivity of [125I]iodopindolol, [125I]iodocyanopindolol, [125I]iodohydroxybenzylpindolol and [3H]dihydroalprenolol for beta-1 and beta-2 adrenergic receptors was assessed by inhibiting the binding of each radioligand with the beta-1-selective unlabeled ligand ICI 89,406 at increasing concentrations of the radioligand, using membranes prepared from C6 glioma cells, which have both beta-1 and beta-2 adrenergic receptors. Scatchard plots for all four radioligands were linear, with correlation coefficients greater than 0.95. [125I]Iodopindolol and [125I]iodocyanopindolol were 3.2- and 2-fold selective, respectively, and [125I]iodohydroxybenzylpindolol and [3H]dihydroalprenolol were 5.8- and 2.3-fold selective, respectively, for beta-2 adrenergic receptors. Values obtained for the densities of beta-1 and beta-2 adrenergic receptors and the affinities of the receptors for ICI 89,406 were independent of the radioligand used.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014123

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

1.  Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.

Authors:  C Hoffmann; M R Leitz; S Oberdorf-Maass; M J Lohse; K-N Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-01-17       Impact factor: 3.000

2.  The beta 1- and beta 2-adrenoceptor affinity and beta 1-blocking potency of S- and R-metoprolol.

Authors:  G Wahlund; V Nerme; T Abrahamsson; P O Sjöquist
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

3.  Receptor modification in the brains of spontaneously hypertensive and Wistar-Kyoto rats: regionally specific and selective increase in cerebellar beta 2-adrenoceptors.

Authors:  C R Jones; J M Palacios; D Hoyer; F R Bühler
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

4.  The role of a low beta 1-adrenoceptor selectivity of [3H]CGP-12177 for resolving subtype-selectivity of competitive ligands.

Authors:  C Nanoff; M Freissmuth; W Schütz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

5.  Beta-adrenoreceptors of multiple affinities in a clonal capillary endothelial cell line and its functional implication.

Authors:  S K Das; S Mukherjee; D K Banerjee
Journal:  Mol Cell Biochem       Date:  1994-11-09       Impact factor: 3.396

6.  Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: preliminary evidence for different binding domains.

Authors:  C M Dersch; H C Akunne; J S Partilla; G U Char; B R de Costa; K C Rice; F I Carroll; R B Rothman
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

7.  Atypical responses of rat ileum to pindolol, cyanopindolol and iodocyanopindolol.

Authors:  A Hoey; C Jackson; G Pegg; M Sillence
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

8.  Characterization of propranolol-resistant (-)-[125I]-cyanopindolol binding sites in rat soleus muscle.

Authors:  S J Roberts; P Molenaar; R J Summers
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

9.  Investigations into factors determining the duration of action of the beta 2-adrenoceptor agonist, salmeterol.

Authors:  A T Nials; M J Sumner; M Johnson; R A Coleman
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

10.  Expression of two human beta-adrenergic receptors in Escherichia coli: functional interaction with two forms of the stimulatory G protein.

Authors:  M Freissmuth; E Selzer; S Marullo; W Schütz; A D Strosberg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.